R eproduction is one of the most fundamental human activities, and reproductive function is affected either directly or indirectly by many health interventions. Pregnancy and childbirth are extremely common; in 2013, there were almost 4 million live births in the United States. 1 In addition, approximately 59% of women aged between 15 and 50 years have had at least one child. 2 Cesarean section is by far the most common major surgical procedure performed in the United States. 3 At current cesarean rates of approximately 30%, 1 nearly 20% of all women will ultimately undergo at least one cesarean delivery.
Interventions that delay or prevent pregnancy are similarly common, with 62% of women of reproductive age currently using contraception. 4 Conversely, utilization rates for infertility treatments are increasing 5 ; 10% of pregnant women in one population-based study 6 reported receiving treatment for infertility. Interventions for disorders of the reproductive tract, such as heavy menstrual bleeding or uterine fibroids, may affect reproductive potential. (In the case of hysterectomy, the effect is certain.) In younger patients, some interventions for nonreproductive tract disorders, such as radiation or chemotherapy for cancers, can have a long-term effect on fertility. 7 Given the importance of reproductive outcomes to such a large part of the population-and the extent to which those outcomes are directly or indirectly affected by a range of health interventions-the heterogeneity of approaches used to value these outcomes in economic analyses, as documented by Goldhaber-Fiebert and Brandeau 8 in this edition of Medical Decision Making, is disappointing although not surprising. The most appropriate method for estimating individual or societal values for parenthood has long been a challenge in conventional economics 9 and in health economics, 10 and the issues involved in estimating the value of fertility (i.e., potential parenthood) are even more complex.
Goldhaber-Fiebert and Brandeau issue a welljustified call for greater transparency in reporting; the use of a systematic framework, such as the one outlined in their article; and, most important, the development of guidelines for conducting and reporting on fertility-related outcomes in cost-effectiveness analyses. Such guidelines must address a number of particularly complex issues, including the following:
Differential preferences for fertility throughout lifespan: The desirability of parenthood clearly varies depending on a number of factors. The valuation of a pregnancy voluntarily prevented through the use of contraception or elective abortion is clearly different than the valuation of a pregnancy prevented as a consequence of a disease-or as an adverse effect of disease treatment. For example, most adolescents do not actively seek pregnancy. However, the impact of loss of fertility due to cancer treatment as a teenager will not be felt until the patient desires a pregnancy. How to appropriately account for such future preferences is not clear, especially given the wide range in maternal age at first pregnancy. QALYs for prevented or lost pregnancies: In the context of prenatal screening, Goldhaber-Fiebert and Brandeau acknowledge inconsistencies in calculating quality-adjusted life-years (QALYs) for children born with disabilities but not for losses due to procedural complications and terminations resulting from prenatal diagnoses. 11 Although this is a legitimate criticism, should a similar approach be taken for pregnancies prevented through the use of contraception? Certainly the numbers of such pregnancies and births can be (and have been) estimated, but inclusion of these QALYs would likely have a major impact on economic analyses of contraception. All individuals affected by fertility-related outcomes: How should one aggregate the impact of outcome preferences across the family: parents, child, and, potentially, siblings, as well as the nonnuclear family? Are these preferences different from considering the impact of an individual's illness on family members? What if partner preferences for the pregnancy, or for pregnancy-related outcomes, are different? If fertility-related outcomes are always estimated for multiple individuals, what are the implications for comparing the cost-effectiveness of interventions that affect these outcomes with those that do not? If partner preferences are important, should they be considered for present partners only-or should QALYs of future partners be considered as well? For example, for an unmarried teenager undergoing cancer treatment that affects fertility, the issue of whether to ''wait'' until the time when she would otherwise desire a pregnancy to assign a disutility associated with infertility is complicated enough. Should the disutility also be assigned to her as-yet unknown future partner? What if the infertility itself affects her selection of a partner? Preferences related to process: As noted by Goldhaber-Fiebert and Brandeau, patients often have strong preferences for attributes of the pregnancy and childbirth experience that are not directly related to the discrete health outcomes usually included in studies of effectiveness or cost-effectiveness. How should one weigh the impact of conditions or treatments that may affect the childbirth process or mode of delivery? For example, treatments and conditions may result in the need for intensive monitoring during labor, or cesarean delivery, even though the individual woman would prefer a less medicalized experience. Preference measures: It is not clear that the use of standard gambles or time tradeoffs to elicit utilities relevant to fertility-related outcomes leads to utilities that truly reflect patient preferences, particularly for child outcomes. Parental utilities elicited using standard gambles for acute, usually nonfatal outcomes (e.g., hospitalization for influenza) are consistently higher than those elicited among individual adults for the same events. [12] [13] [14] Utilities also do not capture preferences for attributes such as the process of care. Alternative methods, such as discrete choice experiments, may provide insight into relative preferences for processes and outcomes. Inclusion of event timing as an attribute in discrete choice experiments may also be a way to avoid the complex issue of how to discount preferences appropriately for timing across the lifespan using a single utility value and some presumably nonconstant discount function.
The complexity of these issues is no doubt one of the reasons for the many problems within the existing literature, as highlighted by Goldhaber-Fiebert and Brandeau. Their proposed framework is an excellent start to, at the least, improving consistency and transparency in the conduct and reporting of analyses of interventions affecting fertility. Researchers, authors, and editors should be strongly encouraged to use this new framework. Development of consensus guidance will require multidisciplinary input, including that of clinicians, economists, modelers, ethicists, and policy makers. Although these issues are indeed difficult, failure to address and resolve them will only maintain the status quo, which, as painfully pointed out in the accompanying article, results in a literature that is not particularly helpful to anyone.
